APC has taken a major step this week toward a more efficient, effective regulatory approach for...
This week: Sponsoring The Hill
APC is continuing our Big Beautiful Blueprint Buy — we’re sponsoring content in some of the most influential media outlets with ads aimed squarely at the Trump administration and getting our pharmacy compounding blueprint into the right hands, so that they can act on its recommendations. We started with Politico’s Prescription Pulse, and this week expanded to The Hill’s Health Care newsletter.
Tweaking the survey
The FDA is planning to conduct a survey to collect data on the outsourcing facility landscape — an important goal we enthusiastically support. Having seen the proposed survey, we submitted comments to the agency with a few practical recommendations we felt would encourage more facilities to participate, but would also ensure the results provided more useful information. (We also took the opportunity to remind the agency of the critical role outsourcing facilities play — and could play — in supporting the healthcare system.)
Wasn’t that on the LSAT?
Let’s all shed a tear for poor Novo Nordisk, which might have to shell out $439,000 in attorney fees after a judge threw out its baseless lawsuit against Brooksville Pharmaceuticals in Florida. Pro tip: If you’re going to claim a compounder caused harm to patients, you kinda have to show that a patient was actually harmed, which Novo couldn’t do. Oopsie! (Novo has appealed the ruling, of course.)
Illinois bill needs a compounding tweak
Illinois is considering rescheduling xylazine products (with exceptions for veterinary use) to help curb its use in illegal drugs. That’s good. Unfortunately, as is often the case, the bill contains an important oversight.
In this case, the bill — SB11773 — makes xylazine exempt from the rules governing controlleds when it’s used in most veterinary contexts, but it doesn’t exempt the compounding of xylazine-containing preparations in those same veterinary contexts.
APC wrote to both the majority and minority leaders and several other members of the Illinois House of Representatives (which is considering the senate bill), asking that they add language that includes ‘compounded forms of xylazine labeled for veterinary use and prescribed or dispensed by a licensed veterinarian.’ That simple addition would provide the same protections “while preserving veterinary access to all forms of the drug that might be required for patient care.”
